The paper content was provided in the user message. Let me re-examine key claims:

The harsh critic claims:
1. "OmniGenome is not described at all in the main text" — Let me verify. The paper mentions OmniGenome in §3.1 "This can be attributed to OmniGenome's integration of structural information into its modeling process" and §3.2 "OmniGenome generalizes well to DNA-based tasks, likely due to shared sequence motifs and structural similarities between RNA and DNA." But the critic is right that no architecture, parameter count, training data, or other model specifics are given in the main text. The paper says "details are essential and included in Appendix B" which is not in the provided text.

2. "Table 3 shows 64.41 for Virus CVC, not 74.72" — Let me check. Table 3 shows OmniGenome | 78.51 | 84.72 | 64.41 | 81.73 | 90.04 | 85.22 | 90.39. The text says "For the Virus CVC task, OmniGenome also achieves the best performance with an F1 score of 74.72." This is indeed an inconsistency — 64.41 in the table vs 74.72 in the text.

3. "Table 4 lists 'GFMbench' as a model" — Yes, the last row says "GFMbench" but the surrounding text discusses it as if it were OmniGenome. This looks like a labeling error.

4. The critic claims "no ablation studies" for OmniGenome's structural information claim — This is correct. The paper repeatedly attributes OmniGenome's performance to "structural information" without any controlled comparison.

5. "No rigorous demonstration that GFMBench improves metric reliability, reproducibility, or fairness" — This is correct. The paper claims these improvements but doesn't empirically validate them.

Let me now compose the final review based on my careful analysis, calibrated against similar papers (GeneBench scored 3-6 and was rejected, DGEB scored 5-6 and was rejected, LRB scored 3-6 and was rejected, EasyTPP benchmarking framework scored 3-10 and was accepted as poster).

## Summary

GFMBench is an open-source benchmarking framework for genomic foundation models (GFMs) that integrates four existing benchmark suites (RGB, PGB, GUE, GB) covering 42 million genomic sequences across 75 datasets, and provides an automated evaluation pipeline (AutoBench), unified model/tokenizer wrappers, and a public leaderboard. The paper evaluates 10+ open-source GFMs across diverse DNA and RNA tasks and reports comprehensive performance tables.

## Strengths

- **Addresses a genuine community need.** The paper correctly identifies real problems in GFM evaluation—inconsistent metrics, lack of standardized protocols, reproducibility issues, and the absence of unified benchmarking infrastructure. Providing a single framework that unifies RGB, PGB, GUE, and GB is a practical contribution.

- **Impressive integrative scope.** Combining four benchmark suites, 75 datasets, and 10+ models into one standardized framework with frozen hyperparameters, unified metric implementations, and automated evaluation is substantial engineering that would lower the barrier for comprehensive model evaluation.

- **Cross-modal evaluation concept.** The adaptive benchmarking approach, evaluating RNA-trained models on DNA tasks and vice versa, is a useful paradigm that can reveal cross-domain generalization properties, and some of the reported findings (e.g., RNA-pretrained models performing well on DNA tasks) are interesting even if under-analyzed.

- **Practical design principles.** The framework's design (utility, simplicity, diversity, extensibility, community) and accompanying tools (embedding extraction, RNA design, data augmentation) go beyond a one-off benchmarking paper to offer a usable research toolkit.

## Weaknesses

### Fatal
None.

### Major

- **Conflation of benchmarking framework contribution with under-specified model evaluation.** The paper is nominally about a benchmarking framework, yet the experimental narrative overwhelmingly centers on OmniGenome's superior performance: "OmniGenome achieves the best performance across all [RGB] tasks" (§3.1), "OmniGenome achieves top-tier performance across most [PGB] tasks" (§3.2), "OmniGenome consistently performs well across various genomic benchmarks" (§3.4), and "OmniGenome consistently achieves top-tier performance" (§3.5). However, OmniGenome is not described in the main text—no architecture, parameter count, training data, tokenizer, or pretraining objectives are provided, with details deferred to an unavailable appendix. The resulting take-home message is effectively "an unspecified model called OmniGenome dominates our benchmarks," which is not a reviewable scientific claim. The paper must either document OmniGenome as a proper contribution (with architecture, training, and ablation details) or restrict its role to an illustrative case study with appropriately modest claims.

- **Core framework claims are empirically unsubstantiated.** The two primary conceptual contributions—benchmark standardization improving metric reliability and AutoBench enabling reproducible, fair, adaptive benchmarking—are supported only by conceptual arguments. There are no targeted experiments showing that GFMBench's standardization actually reduces metric variance, eliminates previously reported inconsistencies (the E2EFold motivating example is never revisited), or yields more reproducible results than ad-hoc evaluation. Similarly, there is no demonstration that "adaptive benchmarking" produces cross-benchmark insights beyond what running separate scripts would yield. For a paper whose primary novelty is evaluation methodology, this is a significant evidential gap.

- **Potential conflict of interest with OmniGenome and RGB.** OmniGenome consistently dominates all four benchmark suites, and RGB (the most featured benchmark) is attributed to Yang & Li (2024)—which appears to be the same group that developed OmniGenome. The paper does not disclose this relationship, nor does it provide evidence that evaluation is fair across models (e.g., equal hyperparameter tuning budgets). This undermines confidence in the benchmark's neutrality.

### Minor

- **Overstated causal claims about structural information without ablations.** The paper repeatedly attributes OmniGenome's performance to "incorporation of structural context during pretraining" (§3.1, §3.2, §3.5) without any controlled ablation—no OmniGenome variant without structural pretraining, no comparison controlling for model size or data. This correlation-is-causation inference should be tempered.

- **Inconsistencies in reported results.** Section 3.3 states OmniGenome achieves "an F1 score of 74.72" on Virus CVC, but Table 3 shows 64.41. Table 4 labels the last row as "GFMbench" rather than "OmniGenome" despite the surrounding text discussing it as OmniGenome. For a paper whose core contribution is standardized and reliable evaluation, such internal inconsistencies erode confidence.

- **Missing model-benchmark combinations unexplained.** Several models lack results on certain benchmarks (e.g., Agro-NT on GUE), but the paper does not explain why—whether due to computational constraints, architectural incompatibility, or other reasons. A benchmarking framework should transparently document such gaps.

- **Missing naive/supervised baselines.** The evaluation includes only GFMs and a few traditional structure prediction tools, but no simple supervised baselines (e.g., CNNs trained from scratch on each task). Without these, it is impossible to assess whether foundation model pretraining provides genuine advantages over straightforward task-specific training—a key question for guiding the field.

- **No variance or statistical significance reporting beyond Table 1.** Only Table 1 mentions averaging over five random seeds; Tables 2–4 do not specify whether the same protocol was followed, and no standard deviations are reported anywhere. Without this, claims of model superiority are difficult to evaluate, especially when margins are small.

### Trivial

- Table 4 label "GFMbench" appears to be a copy-paste error for "OmniGenome."

## Nice-to-Haves

- A detailed comparison table of GFMBench vs. existing tools (GenBench, BEACON, RNABench, DEGB, Kipoi) in terms of benchmarks covered, models supported, standardization features, and automation capabilities would substantially strengthen the positioning.

- Visualization of per-model, per-task performance (e.g., a heatmap) would make cross-benchmark patterns more accessible than four separate tables.

- Analysis of why RNA-pretrained models sometimes outperform DNA-specialized models on DNA tasks (Table 2) would add genuine biological insight beyond surface-level observations.

## Removed Points

These points are flagged to be removed, treat them with caution:

- **"OmniGenome may not exist or be released"**: The paper cites it; we treat all cited models as existing. Removed per hard rule.

- **"Reproducibility concerns about OmniGenome"**: While model specification is poor, this is addressed above as a documentation/claim issue, not an availability concern. The harsh critic's claim that OmniGenome is "non-reproducible" in a fundamental sense is softened; the issue is that claims about an undocumented model are overstated, not that the model doesn't exist.

- **"Missing comparison with existing frameworks (GenBench, BEACON, etc.)"**: Demanding detailed empirical comparison with existing frameworks goes beyond the paper's stated scope. Moved to Nice-to-Have; the paper does mention these tools and differentiates directionally, even if not in depth.

- **"No user study or lines-of-code measurement"**: This is a standard demand that is not the norm for benchmark/framework papers. Removed.

- **"Demands for containerization details, OS + CUDA base image"**: Implementation detail nitpick, not a substantive review concern. Removed.

- **"Unfair comparison across models with different parameter counts"**: While a valid observation, benchmarking frameworks routinely evaluate models of different sizes. This is standard practice in the field; controlling for model size would be a nice-to-have, not a flaw. Weakened.

- **"Incomplete task descriptions deferred to appendix"**: Standard practice for conference papers; appendix is the appropriate place for detailed dataset descriptions. Removed as a nitpick.

## Novel Insights

The most interesting empirical finding is that RNA-pretrained models (OmniGenome, RNA-FM) can match or exceed DNA-specialized models on plant DNA benchmarks (PGB, Table 2), suggesting that structural information learned from RNA transfers surprisingly well to DNA tasks—a non-trivial result that deserves deeper investigation. However, the paper fails to distinguish whether this stems from structural pretraining, model size, data overlap, or other confounds, leaving the insight suggestive rather than conclusive.

## Suggestions

1. **Disclose and address the OmniGenome conflict.** Explicitly state the relationship between GFMBench and OmniGenome's developers. Provide full model specifications in the main paper or a clearly accessible appendix. Demonstrate fair evaluation by showing all models received equal hyperparameter tuning budgets.

2. **Add at least one validation experiment.** Show that GFMBench's standardized metrics reproduce previously published results (e.g., on GUE with NT or DNABERT-2), or that standardization reduces variance compared to ad-hoc implementations.

3. **Fix the errors.** Correct the Virus CVC inconsistency (74.72 vs. 64.41), and fix the "GFMbench" label in Table 4.

4. **Add simple supervised baselines.** Include a CNN or logistic regression baseline trained from scratch per task. This is essential context for interpreting whether GFM pretraining provides benefits.

5. **Temper causal claims.** Replace "structural information enhances performance" with correlation language ("models with structural pretraining tend to perform better") unless ablation evidence is provided.

6. **Report variance.** Add standard deviations across seeds for all tables, not just Table 1.

## Score and Decision

**Calibration comparison:**

- **GeneBench** (similar GFM benchmarking paper, aggregated existing benchmarks, under-specified model, limited analysis) → Scores 3, 5, 6 → Rejected/Withdrawn
- **DGEB** (genomic embedding benchmark, similar scope, also limited baselines) → Scores 5, 5, 5, 6 → Rejected
- **LRB** (DNA benchmark paper, also missing analysis) → Scores 3, 5, 6, 6 → Rejected
- **EasyTPP** (benchmarking framework with unified interface, standardized evaluation) → Scores 8, 3, 3, 10 → Accepted (poster)

GFMBench is most similar to GeneBench in type and quality—a benchmarking framework that aggregates existing datasets, evaluates existing models, lacks empirical validation of its standardization claims, has under-specified or over-claimed model contributions, and provides limited analysis beyond surface-level performance tables. The key additional issues here are: (1) the conflation with OmniGenome's undocumented superiority claims and potential conflict of interest, and (2) factual errors in the results tables. These are more severe than GeneBench's issues. However, the engineering effort and community utility of the framework are genuine positives, similar to EasyTPP's value proposition. The framework integration itself is valuable, but the paper as submitted makes claims it cannot support.

MY FINAL SCORE: <pineapple>3.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>